October 2025 Digital Pathology Roundup

The October 2025 digital pathology roundup with Imogen Fitt of Signify Research is here. Recent activity in digital pathology and AI spans new partnerships, implementations, and product launches. Partnerships: Alpenglow Biosciences & VirDx: Collaborating to create large-scale 3D light-sheet microscopy datasets as ground truth for VirDx’s MRI-based prostate cancer diagnostics, using NVIDIA accelerated computing to tightly link radiology and pathology. Aiforia & Siemens Healthineers (Finland): After a broader European deal, Aiforia signed a local co-marketing/sales agreement with Siemens Healthineers’ Finnish affiliate to drive AI adoption in Finnish pathology as part of precision diagnostics. Implementations: Institut Curie: Entered a one-year agreement, funded by ARS Île-de-France, to use Aiforia’s CE-IVD clinical AI tools in routine pathology to support faster, more consistent diagnoses. One Dorset Pathology (NHS): Signed a 7-year managed equipment service to deploy FUJIFILM SYNAPSE® Pathology on AWS, integrating partners like Sysmex, Menarini, Ibex, Barco, and Augnito. The goal is 100% digital reporting and meeting the UK 10-day histology target by early 2026. Moffitt Cancer Center: Will implement four Pramana high-throughput scanners to support clinical and research work, including cytology and blood smears, with phased adoption through 2027. Ouest Pathologie & Dedalus: Planning the largest French roll-out of the integrated Diamic-DeepUnity LIS + imaging platform across Bretagne/Normandie via a 7-year plan starting December 2025, enabling AI, tele-expertise, and unified image management. Product launches & integrations: Aignostics Atlas H&E-TME: Now generally available, offering rapid, single-cell-level TME readouts and >5,000 metrics per image from routine H&E, initially targeting biopharma research. Proscia & Primaa: Integrated a skin AI module into Proscia’s platform for mitoses, hotspots, perineural invasion, and margin metrics in dermatopathology. PathPresenter: Its vendor-agnostic clinical viewer achieved CE-IVDR marking for primary diagnosis in Europe, complementing its FDA 510(k) and enabling broader EU clinical deployments.